Table 2 Early, late and total apoptosis in AML and ALL patients
| Â | Annxine V | P | Annexine&PI | P | Total apoptosis | P |
|---|---|---|---|---|---|---|
AML patients (n = 70) | ||||||
 FAB | ||||||
  APL* (n = 11) | 4.2 (0.3–6.2) | NS | 5.4 (0.9–7.8) | NS | 6.3 (3.1–13.3) | NS |
  Non-APL (n = 59) | 4.3 (0.3–13.6) | 5.3 (0.6–17.1) | 9.8 (1.7–19.3) | |||
 Performance status | ||||||
  0/1 (n = 33) | 5.2 (0.3–9.5) | NS | 5.5 (0.6–14.6) | NS | 12.3 (2.9–18.5) | NS |
  2/3 (n = 37) | 3.9 (1.0–13.6) | 4.1 (0.6–17.2) | 9.6 (1.7–19.3) | |||
 Early death†| ||||||
  Yes (n = 20) | 3.8 (1.0–6.9) | NS | 3.4 (0.7–7.6) | 0.006 | 8.8 (1.7–12.5) | 0.001 |
  No (n = 48) | 4.5 (0.3–13.6) | 5.6 (0.6–17.1) | 12.4 (2.9–19.3) | |||
ALL patients (n = 28) | ||||||
 FAB | ||||||
  B.ALL (n = 16) | 9.1 (2.2–15.9) | 0.001 | 13.4 (11.3–24.1) | 0.001 | 21.8 (14.8–38.0) | NS |
  T.ALL (n = 12) | 15.9 (13.8–18.6) | 7.7 (5.9–9.1) | 23.8 (20.5–27.4) | |||
 Performance status | ||||||
  0/1 (n = 18) | 15.4 (13.5–18.6) | 0.001 | 8.3 (5.9–24.1) | NS | 25.5 (20.5–38.0) | 0.001 |
  2/3 (n = 10) | 6.3 (2.2–9.3) | 12.7 (11.3–13.8) | 19.2 (14.8–22.4) | |||
 Early death | ||||||
  Yes (n = 5) | 3.7 (3.1–8.5) | 0.001 | 12.7 (11.3–13.1) | NS | 15.8 (14.8–22.3) | 0.002 |
  No (n = 23) | 14.6 (2.2–18.6) | 9.1 (5.9–24.1) | 24.0 (14.9–38.0) | |||